Unprecedented demand for Aimovig reflects strong unmet need in Migraine, says Novartis CEO

Logo of Swiss drugmaker Novartis is seen at its headquarters in Basel

While announcing the recent Q2’ 2018 Novartis results, Novartis AG (NVS) CEO Vasant Narasimhan highlighted that, Novartis had an important launch in the quarter with Aimovig, the first-in-class migraine prevention drug with Amgen as the partner, and it’s off to a strong start in the U.S. Vas said that they really see unprecedented demand for this product, which really reflects the strong unmet need for migraine patients for a better preventive therapy, and they believe this bodes well for Europe.

Vas further added that, “We have the CHMP positive opinion in May with an approval expected in Q3. And importantly, we had an Australia registration in July and we’ve already received approval, as well as Switzerland. So globally as well, Aimovig is starting to ramp-up.”

Aimovig (erenumab) was approved and launched in the US for the preventive treatment of migraine in adults. Aimovig, is the first and only FDA-approved treatment to block the calcitonin gene-related peptide receptor (CGRP-R). Novartis co-commercializes Aimovig with Amgen in the US and Novartis has the exclusive rights to Aimovig ex-US, except for Japan. In Europe, Aimovig received a positive CHMP opinion during Q2.

Aimovig LIBERTY data at AAN reinforced the robust and consistent efficacy of Aimovig for migraine patients with multiple treatment failures. Patients taking Aimovig had nearly three-fold higher odds of having their migraine days cut by at least 50%. Long term safety and efficacy data for chronic migraine demonstrated sustained reductions in monthly migraine days and long term safety and tolerability data in episodic migraine showed the safety profile was consistent with that seen in the pivotal trials.


About Pharmascroll:

Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.

To read more news about Migraine, visit https://pharmascroll.com/news-category/migraine/


News Source: Novartis website